Sorsby fundus dystrophy: Novel mutations, novel phenotypic characteristics, and treatment outcomes

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 4, 2015, Pages 2664-2676

  Gliem, Martin ^a   Müller, Philipp L ^a   Mangold, Elisabeth ^b   Holz, Frank G ^a   Bolz, Hanno J ^c,d   Stöhr, Heidi ^e   Weber, Bernhard H F ^e   Issa, Peter Charbel ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Center for Human Genetics ^*  (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Genotype; Phenotype; Sorsby fundus dystrophy; Therapy

Indexed keywords

BEVACIZUMAB; RETINOL; TISSUE INHIBITOR OF METALLOPROTEINASE 3; ANGIOGENESIS INHIBITOR; DNA; MONOCLONAL ANTIBODY; TIMP3 PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE IMAGING; CHORIORETINAL ATROPHY; CHOROIDAL THICKNESS; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMAGE PROCESSING; INDOCYANINE GREEN ANGIOGRAPHY; METAMORPHOSIS; MIDDLE AGED; NIGHT BLINDNESS; OPTICAL COHERENCE TOMOGRAPHY; PHENOTYPE; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DYSTROPHY; SCANNING LASER OPHTHALMOSCOPY; SORSBY FUNDUS DYSTROPHY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; MALE; METABOLISM; MUTATION; OPHTHALMOSCOPY; PATHOLOGY; PEDIGREE; RETINA; RETINAL DYSTROPHIES;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DNA; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MUTATION; OPHTHALMOSCOPY; PEDIGREE; PHENOTYPE; PROSPECTIVE STUDIES; RETINA; RETINAL DYSTROPHIES; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84937727003     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15733     Document Type: Article

References (61)

1. Sorsby A, Mason ME. A fundus dystrophy with unusual features. Br J Ophthalmol. 1949;33:67–97.
2. Weber BH, Vogt G, Pruett RC, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby’s fundus dystrophy. Nat Genet. 1994;8:352–356.
3. Della NG, Campochiaro PA, Zack DJ. Localization of TIMP-3 mRNA expression to the retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1996;37:1921–1924.
4. Fariss RN, Apte SS, Olsen BR, Iwata K, Milam AH. Tissue inhibitor of metalloproteinases-3 is a component of Bruch’s membrane of the eye. Am J Pathol. 1997;150:323–328.
5. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803:55–71.
6. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003;9:407–415.
7. Black RA. TIMP3 checks inflammation. Nat Genet. 2004;36: 934–935.
8. Stohr H, Anand-Apte B. A review and update on the molecular basis of pathogenesis of Sorsby fundus dystrophy. Adv Exp Med Biol. 2012;723:261–267.
9. Steinmetz RL, Polkinghorne PC, Fitzke FW, Kemp CM, Bird AC. Abnormal dark adaptation and rhodopsin kinetics in Sorsby’s fundus dystrophy. Invest Ophthalmol Vis Sci. 1992;33:1633–1636.
10. Sivaprasad S, Webster AR, Egan CA, Bird AC, Tufail A. Clinical course and treatment outcomes of Sorsby fundus dystrophy. Am J Ophthalmol. 2008;146:228–234.
11. Capon MR, Marshall J, Krafft JI, Alexander RA, Hiscott PS, Bird AC. Sorsby’s fundus dystrophy. A light and electron microscopic study. Ophthalmology. 1989;96:1769–1777.
12. Hoskin A, Sehmi K, Bird AC. Sorsby’s pseudoinflammatory macular dystrophy. Br J Ophthalmol. 1981;65:859–865.
13. Felbor U, Stohr H, Amann T, Schonherr U, Apfelstedt-Sylla E, Weber BH. A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby’s fundus dystrophy. J Med Genet. 1996;33:233–236.
14. Eisenberger T, Neuhaus C, Khan AO, et al. Increasing the yield in targeted next-generation sequencing by implicating CNV analysis, non-coding exons and the overall variant load: the example of retinal dystrophies. PLoS One. 2013;8:78496.
15. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7:575–576.
16. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31:3812–3814.
17. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;76:7.1–7.
18. Schmitz-Valckenberg S, Brinkmann CK, Alten F, et al. Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:7640–7646.
19. Fung AT, Stohr H, Weber BF, Holz FG, Yannuzzi LA. Atypical Sorsby fundus dystrophy with a novel Tyr159Cys TIMP-3 mutation. Retin Cases Brief Rep. 2013;7:71–74.
20. Charbel Issa P, Finger RP, Gotting C, Hendig D, Holz FG, Scholl HP. Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology. 2010;117:1406–1414.
21. Barbazetto IA, Hayashi M, Klais CM, Yannuzzi LA, Allikmets R. A novel TIMP3 mutation associated with Sorsby fundus dystrophy. Arch Ophthalmol. 2005;123:542–543.
22. Clarke M, Mitchell KW, Goodship J, et al. Clinical features of a novel TIMP-3 mutation causing Sorsby’s fundus dystrophy: implications for disease mechanism. Br J Ophthalmol. 2001; 85:1429–1431.
23. Felbor U, Benkwitz C, Klein ML, Greenberg J, Gregory CY, Weber BH. Sorsby fundus dystrophy: reevaluation of variable expressivity in patients carrying a TIMP3 founder mutation. Arch Ophthalmol. 1997;115:1569–1571.
24. Felbor U, Stohr H, Amann T, Schonherr U, Weber BH. A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby’s fundus dystrophy with unusual clinical features. Hum Mol Genet. 1995;4:2415–2416.
25. Jacobson SG, Cideciyan AV, Bennett J, Kingsley RM, Sheffield VC, Stone EM. Novel mutation in the TIMP3 gene causes Sorsby fundus dystrophy. Arch Ophthalmol. 2002;120:376–379.
26. Jacobson SG, Cideciyan AV, Regunath G, et al. Night blindness in Sorsby’s fundus dystrophy reversed by vitamin A. Nat Genet. 1995;11:27–32.
27. Lin RJ, Blumenkranz MS, Binkley J, Wu K, Vollrath D. A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy. Am J Ophthalmol. 2006;142:839–848.
28. Saihan Z, Li Z, Rice J, et al. Clinical and biochemical effects of the E139K missense mutation in the TIMP3 gene, associated with Sorsby fundus dystrophy. Mol Vis. 2009;15:1218–1230.
29. Schoenberger SD, Agarwal A. A novel mutation at the Nterminal domain of the TIMP3 gene in Sorsby fundus dystrophy. Retina. 2013;33:429–435.
30. Tabata Y, Isashiki Y, Kamimura K, Nakao K, Ohba N. A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby’s fundus dystrophy with unusual clinical features. Hum Genet. 1998;103:179–182.
31. Akahori M, Tsunoda K, Miyake Y, et al. Dominant mut ations in RP1L1 are responsible for occult macular dystrophy. Am J Hum Genet. 2010;87:424–429.
32. Davidson AE, Sergouniotis P I, Mackay DS, et al. RP1L1 variants are associated with a spectrum of inherited retinal diseases including retinitis pigmentosa a nd occult macular dystrophy. Hum Mutat. 2013;34:506–514.
33. Audo I, Bujakowska KM, Leveillard T, et al. Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases. Orphanet J Rare Dis. 2012;7:8.
34. Gliem M, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P. An update on the ocular phenotype in patient s with pseudoxanthoma elasticum. Front Genet. 2013;4:14.
35. Chang AA, Morse LS, Handa JT, et al. Histologic localization of indocyanine green dye in aging primate and human ocular tissues with clinical angiographic correlation. Ophthalmology. 1998;105:1060–1068.
36. Chang AA, Zhu M, Billson F. The interaction of indocyanine green with human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2005;46:1463–1467.
37. Hamilton WK, Ewing CC, Ives EJ, Carruthers JD. Sorsby’s fundus dystrophy. Ophthalmology. 1989;96:1755–1762.
38. Capon MR, Polkinghorne PJ, Fitzke FW, Bird AC. Sorsby’s pseudoinflammatory macula dystrophy—Sorsby’s fundus dystrophies. Eye (Lond). 1988;2;114–122.
39. Polkinghorne PJ, Capon MR, Berninger T, Lyness AL, Sehmi K, Bird AC. Sorsby’s fundus dystrophy. A clinical study. Ophthalmology. 1989;96:1763–1768.
40. Peters AL, Greenberg J. Sorsby’s fundus dystrophy. A South African family with a point mutation on the tissue inhibitor of metalloproteinases-3 gene on chromosome 22. Retina. 1995; 15:480–485.
41. Carrero-Valenzuela RD, Klein ML, Weleber RG, Murphey WH, Litt M. Sorsby fundus dystrophy. A family with the Ser181Cys mutation of the tissue inhibitor of metalloproteinases 3. Arch Ophthalmol. 1996;114:737–738.
42. Wu G, Pruett RC, Baldinger J, Hirose T. Hereditary hemorrhagic macular dystrophy. Am J Ophthalmol. 1991;111:294–301.
43. Felbor U, Suvanto EA, Forsius HR, Eriksson AW, Weber BH. Autosomal recessive Sorsby fundus dystrophy revisited: molecular evidence for dominant inheritance. Am J Hum Genet. 1997;60:57–62.
44. Forsius HR, Eriksson AW, Suvanto EA, Alanko HI. Pseudoinflammatory fundus dystrophy with autosomal recessive inheritance. Am J Ophthalmol. 1982;94:634–649.
45. Eriksson AW, Suvanto EA, Frants RR, Forsius HR. Pseudoinflammatory fundus dystrophy: a follow-up study. Clin Genet. 1990;38:21–32.
46. Langton KP, McKie N, Curtis A, et al. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby’s fundus dystrophy. J Biol Chem. 2000; 275:27027–27031.
47. Isashiki Y, Tabata Y, Kamimura K, Ohba N. Sorsby’s fundus dystrophy in two Japanese families with unusual clinical features. Jpn J Ophthalmol. 1999;43:472–480.
48. Carr RE, Noble KG. Pseudoinflammatory macular dystrophy. Trans Am Ophthalmol Soc. 1977;75:255–271.
49. Fraser HB, Wallace DC. Sorsby’s familial pseudo-inflammatory macular dystrophy. Am J Ophthalmol. 1971;71:1216–1220.
50. Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HP, Schmitz-Valckenberg S. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol. 2007; 143:463–472.
51. Klein ML, Ferris FL III, Francis PJ, et al. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology. 2010;117:1554–1559.
52. Fujinami K, Lois N, Davidson AE, et al. A longitudinal study of Stargardt disease: clinical and electrophysiologic assessme nt,progression, and genotype correlations. Am J Ophthalmol. 2013;155:1075–1088.
53. Chen B, Tosha C, Gorin MB, Nusinowitz S. Analysis of autofluorescent retinal images and measurement of atrophic lesion growth in Stargardt disease. Exp Eye Res. 2010;91:143–152.
54. McBain VA, Townend J, Lois N. Progression of retinal pigment epithelial atrophy in Stargardt disease. Am J Ophthalmol. 2012;154:146–154.
55. Gliem M, Fimmers R, Muller PL, et al. Choroidal changes associated with Bruch membrane pathology in pseudoxanthoma elasticum. Am J Ophthalmol. 2014;158:198–207.
56. Balaskas K, Hovan M, Mahmood S, Bishop P. Ranibizumab for the management of Sorsby fundus dystrophy. Eye (Lond). 2013;27:101–102.
57. Kapoor KG, Bakri SJ. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization due to Sorsby macular dystrophy. J Ocul Pharmacol Ther. 2013;29: 444–447.
58. Gray TL, Wong H, Raymond GL. Choroidal neovascularization secondary to Sorsby fundus dsytrophy treated with intravitreal bevacizumab. Retin Cases Brief Rep. 2012;6:193–196.
59. Gemenetzi MK, Luff AJ, Lotery AJ. Successful treatment of choroidal neovascularization secondary to Sorsby fundus dystrophy with intravitreal bevacizumab. Retin Cases Brief Rep. 2011;5:132–135.
60. Holz FG, Haimovici R, Wagner DG, Bird AC. Recurrent choroidal neovascularization after laser photocoagulation in Sorsby’s fundus dystrophy. Retina. 1994;14:329–334.
61. Sibulesky L, Hayes KC, Pronczuk A, Weigel-DiFranco C, Rosner B, Berson EL. Safety of <7500 RE (<25000 IU) vitamin A daily in adults with retinitis pigmentosa. Am J Clin Nutr. 1999;69: 656–663.